Related Experiment Video
Updated: May 5, 2026

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Exhaled nitric oxide predicts persistence of wheezing, exacerbations, and decline in lung function in wheezy infants
M Elliott1, S L Heltshe, D C Stamey
1Division of Pulmonary Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Insights
Single-breath fraction of exhaled nitric oxide (SB-FENO) effectively predicts persistent wheezing in young children. This method outperformed other tests in forecasting exacerbations and wheezing duration.
Area of Science:
- Pediatric Pulmonology
- Respiratory Medicine
- Biomarkers in Asthma
Background:
- Limited data exists on predicting wheezing persistence, exacerbations, and lung function decline in infants with recurrent wheezing.
- Fraction of exhaled nitric oxide (FENO) is a potential non-invasive biomarker.
Purpose of the Study:
- To compare the predictive values of single-breath FENO (SB-FENO), tidal-breathing FENO (tidal-FENO), bronchodilator responsiveness (BDR), and the Asthma Predictive Index (API) for clinical outcomes in infants with recurrent wheezing.
- To assess these markers' ability to predict wheezing persistence, exacerbations, and lung function changes up to age 3 years.
Main Methods:
- A longitudinal cohort study enrolled 44 infants and toddlers with recurrent wheezing.
- Infant pulmonary function tests (iPFTs), SB-FENO, and tidal-FENO were measured at enrollment.
- Clinical outcomes and follow-up iPFTs were assessed at age 3 years.
Main Results:
- An enrollment SB-FENO level ≥ 30 p.p.b. predicted wheezing persistence at age 3 years with high accuracy (AUC 0.86).
- SB-FENO demonstrated superior sensitivity and specificity compared to tidal-FENO, BDR, and API for predicting wheezing persistence and exacerbations.
- Both SB-FENO and tidal-FENO were associated with a decline in lung function (FEV0.5 and FEF25-75) by age 3 years.
Conclusions:
- SB-FENO is a more effective predictor of future exacerbations and persistent wheezing in infants and toddlers than tidal-FENO, BDR, or API.
- Elevated SB-FENO and tidal-FENO levels at enrollment may indicate a risk of long-term lung function decline.
Background:
There are limited data assessing the predictive value of fraction of exhaled nitric oxide (FENO ) for persistence of wheezing, exacerbations, or lung function change over time in infants/toddlers with recurrent wheezing.
Objectives:
In an ongoing longitudinal cohort of infants and toddlers with recurrent wheezing, we compared predictive values of single-breath FENO (SB-FENO ), tidal-breathing mixed expired FENO (tidal-FENO ), bronchodilator responsiveness (BDR) and the Castro-Rodriquez Asthma Predictive Index (API) for persistence of wheezing, exacerbations and lung function change through age 3 years.
Methods:
Enrolment forced expiratory flows and volumes infant pulmonary function tests (iPFTs) were measured in 44 infants/toddlers using the raised volume rapid thoracoabdominal compression method. SB-FENO was measured at 50 mL/s, and tidal-FENO was measured during awake tidal breathing. Clinical outcomes were assessed at age 3 years in 42 infants. Follow-up iPFTs were completed between ages 2.5-3 years in 32 subjects.
Results:
An enrolment SB-FENO concentration ≥ 30 p.p.b. predicted persistence of wheezing at age 3 years with a sensitivity of 77%, a specificity of 94%, and an area under the curve (AUC) of 0.86 (95% CI: 0.74-0.98). The sensitivity, specificity, positive predictive, and negative predictive values of SB-FENO for persistence of wheezing and exacerbations were superior to tidal-FENO , BDR, and the API. SB-FENO ≥ 30 p.p.b. and tidal-FENO ≥ 7 p.p.b. measured at enrolment was associated with a decline in both FEV0.5 and FEF25-75 between enrolment and age 3 years.
Conclusions:
In wheezy infants/toddlers, SB-FENO was superior to tidal-FENO , BDR, and the API in predicting future exacerbations and persistence of wheezing at age 3 years. Both SB-FENO and tidal-FENO were associated with lung function decline over time.
Related Concept Videos
Asthma III: Clinical Manifestations
Asthma I: Introduction
Pulmonary Cycle: Exhalation
Asthma-I: Introduction
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Breathing

